Which opportunities do we pursue? Where, within the many strands of our business, will new investment create the most positive return?

Over to our Portfolio Committee. Composed of senior company executives drawn from science and commercial management, as well as outstanding external scientists, the committee is charged with maximising our investments in science, commercially and strategically. As part of this role, it identifies the wider market opportunities that spring from our cross-business co-ordination.

The Portfolio Committee meets at least twice a year. It monitors the progress of our total science portfolio, and reviews and approves our investment in research. Through the Chief Executive, the committee also recommends to the Board the overall balance of investment in science within the group.

The range of opportunities available from our science and commercial base is virtually unmatched within the total healthcare market we cover. Our discovery systems business area, for instance, is looking at significant new opportunities in the diagnostic field. Similarly, our medical diagnostics business area is rapidly giving us greater insight into changes in the body at the molecular level. The Portfolio Committee’s task is to make sure we make the most of these exciting opportunities.

Amersham’s Portfolio Committee
Andrew Carr
President, Amersham Biosciences
Bill Castell
Chief Executive
Bill Clarke
EVP R&D, Amersham Health
Jean-Michel Cosséry
EVP Product Strategy, Amersham Health
Peter Ehrenheim
President, protein separations
Mike Hayes
Chief Technology Officer, Amersham Biosciences
Giles Kerr
Finance Director
Peter Loescher
President, Amersham Health
Keith Peters
Regius Professor of Physic, Cambridge and Non-Executive Director, Amersham plc
Tony Rollins
VP, Group Intellectual Property
James Rothman
Vice Chairman, Sloan- Kettering Institute and Chief Scientist, discovery systems
Mike Stevens
Director, Corporate Development
Mathias Uhlén
Professor of Biotechnology, Royal Institute of Technology, Stockholm and Non-Executive Director, Amersham plc